 | • レポートコード：MRC23Q37396 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のジェネリックトファシチニブ市場について調査・分析し、世界のジェネリックトファシチニブ市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（錠剤、内用液剤）、用途別セグメント分析（病院、小売）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、CTTQ、CSPC、Qilu Pharmaceutical、Simcere、Kelun、Wanbangなどが含まれています。世界のジェネリックトファシチニブ市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ジェネリックトファシチニブ市場規模を推定する際に考慮しました。本レポートは、ジェネリックトファシチニブの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ジェネリックトファシチニブに関するビジネス上の意思決定に役立てることを目的としています。 ・ジェネリックトファシチニブ市場の概要 - 製品の定義 - ジェネリックトファシチニブのタイプ別セグメント - 世界のジェネリックトファシチニブ市場規模：タイプ別分析（錠剤、内用液剤） - ジェネリックトファシチニブの用途別セグメント - 世界のジェネリックトファシチニブ市場規模：用途別分析（病院、小売） - 世界のジェネリックトファシチニブ市場規模予測（2018年-2029年） - ジェネリックトファシチニブの平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - ジェネリックトファシチニブ市場の競争状況およびトレンド ・ジェネリックトファシチニブの地域別市場規模 - 北米のジェネリックトファシチニブ市場規模（2018年-2029年） - アメリカのジェネリックトファシチニブ市場規模（2018年-2029年） - ヨーロッパのジェネリックトファシチニブ市場規模（2018年-2029年） - アジア太平洋のジェネリックトファシチニブ市場規模（2018年-2029年） - 中国のジェネリックトファシチニブ市場規模（2018年-2029年） - 日本のジェネリックトファシチニブ市場規模（2018年-2029年） - 韓国のジェネリックトファシチニブ市場規模（2018年-2029年） - インドのジェネリックトファシチニブ市場規模（2018年-2029年） - オーストラリアのジェネリックトファシチニブ市場規模（2018年-2029年） - 中南米のジェネリックトファシチニブ市場規模（2018年-2029年） - 中東・アフリカのジェネリックトファシチニブ市場規模（2018年-2029年） ・タイプ別セグメント：錠剤、内用液剤 - 世界のジェネリックトファシチニブのタイプ別販売量（2018年-2023年） - 世界のジェネリックトファシチニブのタイプ別売上（2018年-2023年） - 世界のジェネリックトファシチニブのタイプ別価格 ・用途別セグメント：病院、小売 - 世界のジェネリックトファシチニブの用途別販売量（2018年-2023年） - 世界のジェネリックトファシチニブの用途別売上（2018年-2023年） - 世界のジェネリックトファシチニブの用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 CTTQ、CSPC、Qilu Pharmaceutical、Simcere、Kelun、Wanbang ・産業チェーンと販売チャネルの分析 - ジェネリックトファシチニブ産業チェーン分析 - ジェネリックトファシチニブの主要原材料 - ジェネリックトファシチニブの販売チャネル - ジェネリックトファシチニブのディストリビューター - ジェネリックトファシチニブの主要顧客 ・ジェネリックトファシチニブ市場ダイナミクス - ジェネリックトファシチニブの業界動向 - ジェネリックトファシチニブ市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Generic Tofacitinib market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Generic Tofacitinib is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Generic Tofacitinib is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Generic Tofacitinib include CTTQ, CSPC, Qilu Pharmaceutical, Simcere, Kelun and Wanbang, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic Tofacitinib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Tofacitinib.
The Generic Tofacitinib market size, estimations, and forecasts are provided in terms of sales volume (Ton) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Generic Tofacitinib market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic Tofacitinib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
CTTQ
CSPC
Qilu Pharmaceutical
Simcere
Kelun
Wanbang
Segment by Type
Tablet
Oral Liquid
Segment by Application
Hospital
Retail
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Generic Tofacitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Generic Tofacitinib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Generic Tofacitinib Market Overview
1.1 Product Overview and Scope of Generic Tofacitinib
1.2 Generic Tofacitinib Segment by Type
1.2.1 Global Generic Tofacitinib Market Value Comparison by Type (2023-2029)
1.2.2 Tablet
1.2.3 Oral Liquid
1.3 Generic Tofacitinib Segment by Application
1.3.1 Global Generic Tofacitinib Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Retail
1.4 Global Generic Tofacitinib Market Size Estimates and Forecasts
1.4.1 Global Generic Tofacitinib Revenue 2018-2029
1.4.2 Global Generic Tofacitinib Sales 2018-2029
1.4.3 Global Generic Tofacitinib Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Generic Tofacitinib Market Competition by Manufacturers
2.1 Global Generic Tofacitinib Sales Market Share by Manufacturers (2018-2023)
2.2 Global Generic Tofacitinib Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Generic Tofacitinib Average Price by Manufacturers (2018-2023)
2.4 Global Generic Tofacitinib Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Generic Tofacitinib, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Generic Tofacitinib, Product Type & Application
2.7 Generic Tofacitinib Market Competitive Situation and Trends
2.7.1 Generic Tofacitinib Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Generic Tofacitinib Players Market Share by Revenue
2.7.3 Global Generic Tofacitinib Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Generic Tofacitinib Retrospective Market Scenario by Region
3.1 Global Generic Tofacitinib Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Generic Tofacitinib Global Generic Tofacitinib Sales by Region: 2018-2029
3.2.1 Global Generic Tofacitinib Sales by Region: 2018-2023
3.2.2 Global Generic Tofacitinib Sales by Region: 2024-2029
3.3 Global Generic Tofacitinib Global Generic Tofacitinib Revenue by Region: 2018-2029
3.3.1 Global Generic Tofacitinib Revenue by Region: 2018-2023
3.3.2 Global Generic Tofacitinib Revenue by Region: 2024-2029
3.4 North America Generic Tofacitinib Market Facts & Figures by Country
3.4.1 North America Generic Tofacitinib Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Generic Tofacitinib Sales by Country (2018-2029)
3.4.3 North America Generic Tofacitinib Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Generic Tofacitinib Market Facts & Figures by Country
3.5.1 Europe Generic Tofacitinib Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Generic Tofacitinib Sales by Country (2018-2029)
3.5.3 Europe Generic Tofacitinib Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Generic Tofacitinib Market Facts & Figures by Country
3.6.1 Asia Pacific Generic Tofacitinib Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Generic Tofacitinib Sales by Country (2018-2029)
3.6.3 Asia Pacific Generic Tofacitinib Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Generic Tofacitinib Market Facts & Figures by Country
3.7.1 Latin America Generic Tofacitinib Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Generic Tofacitinib Sales by Country (2018-2029)
3.7.3 Latin America Generic Tofacitinib Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Generic Tofacitinib Market Facts & Figures by Country
3.8.1 Middle East and Africa Generic Tofacitinib Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Generic Tofacitinib Sales by Country (2018-2029)
3.8.3 Middle East and Africa Generic Tofacitinib Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Generic Tofacitinib Sales by Type (2018-2029)
4.1.1 Global Generic Tofacitinib Sales by Type (2018-2023)
4.1.2 Global Generic Tofacitinib Sales by Type (2024-2029)
4.1.3 Global Generic Tofacitinib Sales Market Share by Type (2018-2029)
4.2 Global Generic Tofacitinib Revenue by Type (2018-2029)
4.2.1 Global Generic Tofacitinib Revenue by Type (2018-2023)
4.2.2 Global Generic Tofacitinib Revenue by Type (2024-2029)
4.2.3 Global Generic Tofacitinib Revenue Market Share by Type (2018-2029)
4.3 Global Generic Tofacitinib Price by Type (2018-2029)
5 Segment by Application
5.1 Global Generic Tofacitinib Sales by Application (2018-2029)
5.1.1 Global Generic Tofacitinib Sales by Application (2018-2023)
5.1.2 Global Generic Tofacitinib Sales by Application (2024-2029)
5.1.3 Global Generic Tofacitinib Sales Market Share by Application (2018-2029)
5.2 Global Generic Tofacitinib Revenue by Application (2018-2029)
5.2.1 Global Generic Tofacitinib Revenue by Application (2018-2023)
5.2.2 Global Generic Tofacitinib Revenue by Application (2024-2029)
5.2.3 Global Generic Tofacitinib Revenue Market Share by Application (2018-2029)
5.3 Global Generic Tofacitinib Price by Application (2018-2029)
6 Key Companies Profiled
6.1 CTTQ
6.1.1 CTTQ Corporation Information
6.1.2 CTTQ Description and Business Overview
6.1.3 CTTQ Generic Tofacitinib Sales, Revenue and Gross Margin (2018-2023)
6.1.4 CTTQ Generic Tofacitinib Product Portfolio
6.1.5 CTTQ Recent Developments/Updates
6.2 CSPC
6.2.1 CSPC Corporation Information
6.2.2 CSPC Description and Business Overview
6.2.3 CSPC Generic Tofacitinib Sales, Revenue and Gross Margin (2018-2023)
6.2.4 CSPC Generic Tofacitinib Product Portfolio
6.2.5 CSPC Recent Developments/Updates
6.3 Qilu Pharmaceutical
6.3.1 Qilu Pharmaceutical Corporation Information
6.3.2 Qilu Pharmaceutical Description and Business Overview
6.3.3 Qilu Pharmaceutical Generic Tofacitinib Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Qilu Pharmaceutical Generic Tofacitinib Product Portfolio
6.3.5 Qilu Pharmaceutical Recent Developments/Updates
6.4 Simcere
6.4.1 Simcere Corporation Information
6.4.2 Simcere Description and Business Overview
6.4.3 Simcere Generic Tofacitinib Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Simcere Generic Tofacitinib Product Portfolio
6.4.5 Simcere Recent Developments/Updates
6.5 Kelun
6.5.1 Kelun Corporation Information
6.5.2 Kelun Description and Business Overview
6.5.3 Kelun Generic Tofacitinib Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Kelun Generic Tofacitinib Product Portfolio
6.5.5 Kelun Recent Developments/Updates
6.6 Wanbang
6.6.1 Wanbang Corporation Information
6.6.2 Wanbang Description and Business Overview
6.6.3 Wanbang Generic Tofacitinib Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Wanbang Generic Tofacitinib Product Portfolio
6.6.5 Wanbang Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Generic Tofacitinib Industry Chain Analysis
7.2 Generic Tofacitinib Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Generic Tofacitinib Production Mode & Process
7.4 Generic Tofacitinib Sales and Marketing
7.4.1 Generic Tofacitinib Sales Channels
7.4.2 Generic Tofacitinib Distributors
7.5 Generic Tofacitinib Customers
8 Generic Tofacitinib Market Dynamics
8.1 Generic Tofacitinib Industry Trends
8.2 Generic Tofacitinib Market Drivers
8.3 Generic Tofacitinib Market Challenges
8.4 Generic Tofacitinib Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer